Management of anticoagulation in patients with metastatic castration–resistant prostate cancer receiving abiraterone + prednisone
- 77 Downloads
Abiraterone has been proven to be an effective agent used in the management of metastatic castration–resistant prostate cancer, significantly improving overall and progression-free survival. Due to the pharmacodynamic and pharmacokinetic properties of abiraterone, concurrent use with anticoagulation may pose a challenge for clinicians. Thrombosis within the cancer setting continues to increase patient mortality; therefore, appropriate anticoagulation through the use of a management algorithm can reduce adverse events and increase quality of life.
A review of the literature was preformed by a medical oncologist, haematologist and pharmacists to identify relevant randomized controlled trials, meta-analyses and retrospective studies. Major society guidelines were reviewed to further aid in developing the anticoagulation protocol for non-valvular atrial fibrillation and venous thromboembolism within this patient population. After reviewing the literature, a clinical framework was designed to aid clinicians in the management of those patients receiving abiraterone concurrently with an anticoagulant.
In this review, we describe the potential interactions between abiraterone and various anticoagulants and provide management strategies based on the most recent literature for atrial fibrillation, venous thromboembolism and mechanical heart valves to avoid potential drug–drug interactions.
Abiraterone therapy has become a mainstay of the management of advanced prostate cancer and is often used over prolonged years. In this review, we have summarized a framework of how to use abiraterone in men with prostate cancer on anticoagulants. Evidence available to date suggests that patients with an indication for anticoagulation such as atrial fibrillation, venous thromboembolism and mechanical heart valves can be treated safely with abiraterone in the appropriate setting, with appropriate monitoring.
KeywordsAnticoagulation Abiraterone Pharmacokinetics Supportive care Prostate cancer
I would like to extend sincere gratitude to Dr. Alia Thawer; she provided extensive support in addition to her expertise that greatly assisted this research. I would also like to show gratitude to Dr. Thomas McFarlane, Dr. Anne McLeod and Dr. Urban Emmenegger for sharing their pearls of wisdom and assistance in critical appraisal during the course of this research.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest. Dr. Urban Emmenegger has received clinical research support (personal and institutional) from Janssen Inc., Canada, and has attended advisory board meetings.
The authors of this manuscript have full control of the data presented. We agree to let the Journal of Supportive Care in Cancer review the data if requested.
- 4.Marinigh R, Lip GYH, Fiotti N, Giansanate C, Lane DA (2010) Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. JACC 56(11). https://doi.org/10.1016/j.jacc.2010.05.028
- 7.Lane DA, Skjoth F, Lip GYH, Larsen TB, Kotecha D (2017) Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. JAHA 6(5). https://doi.org/10.1161/JAHA.116.00515
- 19.Narum S, Westergren T, Klemp M (2014) Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open 4(5). https://doi.org/10.1136/bmjopen-2013-004587
- 25.Dickmann B, Ahlbrecht J, Ay C, Dunkler D, Thaler J, Scheithauer W, Quehenberger P, Zielinski C, Pabinger I (2013) Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica. 98:1309–1314. https://doi.org/10.3324/haematol.2012.073338 CrossRefGoogle Scholar
- 32.Di Minno A, Frigerio B, Spadarella G. et. al. Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood Rev 2017; 31(4): 193–203Google Scholar
- 38.Young A, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol:JCO2018788034. https://doi.org/10.1200/JCO.2018.78.8034
- 39.Bayer INC (2018) Xarelto product monograph. Bayer INC., MississaugaGoogle Scholar
- 41.Servier Pharmaceuticals (2016) Lixiana product monograph. Servier Canada INC., LavalGoogle Scholar
- 50.Pfizer Pharmaceuticals (2016) Eliquis product monograph. Pfizer Canada INC., KirklandGoogle Scholar
- 55.Boehringer Ingelhem Pharmaceuticals (2016) Pradaxa product monograph. Boehringer Ingelheim Canada Ltd, BurlingtonGoogle Scholar
- 59.Camm AJ (2001) Atrial fibrillation: is there a role for low-molecular-weight heparin? Clin Cariol 24(3):115–119Google Scholar
- 64.Nishimura RA, Otto CM, Bonow RO et al (2017) 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. JACC. 70(2):252–289CrossRefGoogle Scholar
- 65.Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest physicians evidence-based clinical practice guidelines. CHEST 141(2):576–600. https://doi.org/10.1378/chest.11-2305
- 66.Van de Werf F, Brueckmann M, Connolly SJ et al (2012) A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). AHJ. 163(6):931–937CrossRefGoogle Scholar
- 67.Goldberg T, Berrios-Colon E (2013) Abiraterone (Zytiga), a novel agent for the management of castration-resistant prostate cancer. PT. 38(1):23–26Google Scholar
- 68.Carrier M, Blais N, Crowther M et al (2018) Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. Curr Oncol 5:329–337Google Scholar